Analyst Salveen Richter of Goldman Sachs maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), reducing the price target ...

Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.

Vertex Pharmaceuticals stock (NASDAQ ... For perspective, R&D expenses rose 78% since 2021, versus a 40% rise in sales. With a rise in Trikafta demand, the investors have assigned a higher ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “outperform” rating reaffirmed by stock analysts at William Blair in a research report issued on Monday,RTT News reports.

The investment community will be closely monitoring the performance of Vertex Pharmaceuticals in its forthcoming earnings report. It is anticipated that the company will report an EPS of $4 ...

Get the Real Story Behind Every Major Earnings Report Vertex Pharmaceuticals Inc. VRTX shares are trading higher Friday following two major developments that strengthen its position in both pain ...

Vertex Pharmaceuticals (VRTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Terence ...

Shares of Vertex Pharmaceuticals Inc. surged ahead of Friday’s market open after the Food and Drug Administration approved the company’s non-opioid pain treatment. It’s the first new class ...

A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug Administration (FDA). The company’s "first-in-class" suzetrigine pain pill ...

The U.S. Food and Drug Administration has approved a new non-opioid pain medication developed by Boston-based Vertex Pharmaceuticals. The drug, which is called suzetrigine and will be sold under ...

Investors will be eagerly watching for the performance of Vertex Pharmaceuticals in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on February 10 ...